News · Heart & Metabolic
Ultrasound-guided stenting cut cardiac deaths in East Asian trials and not in anyone else's
Guidelines increasingly recommend imaging inside the artery while placing a stent. Pooling 17 trials and 14,033 patients found the benefit sat almost entirely in one part of the world.
- Pooled across all trials, imaging guidance tracked fewer cardiac deaths.
- In East Asian trials the reduction was large and consistent.
- In trials run elsewhere there was no reduction at all.
- The gap between regions was large enough that chance is an unlikely explanation.
- 17 randomized trials and 14,033 patients, but only 7 from outside East Asia.
When a cardiologist opens a blocked artery and props it with a stent, the picture they work from is an X-ray of the channel the blood flows through. It shows the space, not the wall.
Threading a tiny ultrasound probe into the vessel shows the wall, and whether the stent is properly expanded against it. Badly seated stents cause clots and re-narrowing months later, so seeing them ought to help.
Trial after trial has said it does. Almost all of those trials were run in the same part of the world.
Why the trials were split by region before looking
Writing in the European Heart Journal, researchers pooled every randomized trial comparing the two approaches and, before looking, specified the thing they wanted to test: whether the benefit differed by region.
That ordering matters. A geographic split discovered after the fact in a dataset is a curiosity. A geographic split that a team predicted in advance and then found is a result.
Seventeen trials qualified, covering 14,033 patients. Ten came from East Asia, seven from elsewhere. Previously the pooled estimate had been reported as a single global figure, with the regional imbalance behind it left unexamined.
What pooling all 17 stent trials showed
Taken together, the imaging approach was associated with fewer cardiac deaths, by roughly 30% in relative terms.
That is the number that would appear in a guideline, and on its own it looks like a settled question.
Why cardiac deaths fell only in East Asian trials
Inside the East Asian trials, cardiac deaths fell by about 44%, with a tight range and consistency across studies.
Inside the trials run elsewhere, they did not fall. The estimate sits slightly above one, meaning marginally more deaths in the imaging group, with a range wide enough to include a meaningful benefit and a meaningful harm.
The test for whether region changed the effect was itself significant. This is not two estimates that happen to differ; it is a difference the analysis was designed to detect and did.
What could explain the regional gap in stenting
Not genetics, most likely, and the study cannot say.
The plausible candidates are all about how medicine is practised rather than who is being treated. Operators differ in how routinely they use the technique and therefore in how skilled they are with it. Health systems differ in which patients reach a stent at all, and in the background rate of the events being counted. And seeing a poorly seated stent only helps if the operator then does something about it, which is a habit rather than a technology.
Why seven non-Asian trials is a thin base
Seven trials and fewer than 4,000 patients is a thin evidence base for the non-Asian half.
That asymmetry matters. A null result from a small number of smaller trials is not the same as a demonstration that the technique does not work; it is a demonstration that it has not yet been shown to. The honest statement is that the benefit is established in one setting and unproven in the other.
Why a guideline should ask where trials were run
Angioplasty is a procedure to open narrowed or blocked blood vessels that supply blood to your heart, and it is performed hundreds of thousands of times a year.
The general lesson is about how evidence travels. A pooled estimate assembled mostly from one region and then applied everywhere assumes the procedure means the same thing everywhere, and this analysis is a direct test of that assumption failing. Before a guideline generalizes a result, it is worth asking where the trials were run.
People also ask
What did the analysis find?
Seventeen trials (14,033 patients; 10 East Asian with 10,155 patients, 7 non-Asian with 3,878) were pooled. The overall risk ratio for cardiac death was 0.71 (95% CI 0.53-0.94; P = .022), with a significant geographic interaction: East Asian risk ratio 0.56 (0.46-0.69) against non-Asian 1.23 (0.85-1.76).
What is intravascular ultrasound guidance?
A miniature ultrasound probe threaded into the coronary artery during the procedure, so the operator can see the vessel wall and the stent from inside rather than relying on the external X-ray picture alone.
Why would it help?
Because the X-ray view shows the channel blood flows through, not the wall. Imaging from inside reveals whether the stent is fully expanded and properly seated, and poorly deployed stents are a known cause of later clots and re-narrowing.
What is effect modification?
When a treatment works differently in different groups, rather than simply working better or worse overall. Here the pre-specified question was whether region changed the size of the benefit, and the test for that was significant.
Could this be about genetics?
Unlikely to be mainly that. More plausible explanations are differences in how the procedure is performed, which patients are selected for the trials, how thoroughly the imaging is acted on, and the background rate of events, all of which vary between health systems.
Does this mean the technique does not work outside East Asia?
It means the trials run elsewhere have not shown benefit, and there are only seven of them with under 4,000 patients between them. Absence of evidence at that size is a weaker claim than evidence of absence.
What does this mean for a patient facing a stent?
Nothing to act on individually; whether to use imaging guidance is an operator decision made during the procedure. This is general information rather than medical advice.